CBER Director Midthun Retiring; Legacy Includes Biosimilar Principles, Avastin Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
While CBER is often perceived to be as much focused on research as it is on application review, Midthun was central to many key policy debates.